Lam, Carolyn S.P.

Empagliflozin in heart failure with a preserved ejection fraction

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 4,874

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 2,884

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,430

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association

Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,665

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,599

Vericiguat in patients with heart failure and reduced ejection fraction

Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,358

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 996

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 829

Epidemiology and clinical course of heart failure with preserved ejection fraction

Lam, C. S. P., Donal, E., Kraigher-Krainer, E., & Vasan, R. S. (2011) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 709

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

Shah, S. J., Lam, C. S. P., Svedlund, S., Saraste, A., Hage, C., Tan, R.-S., Beussink-Nelson, L., Ljung Faxén, U., Fermer, M. L., Broberg, M. A., et al. (2018) · European Heart Journal

Cardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics

Cited by 656

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Mentz, R. J., Kelly, J. P., von Lueder, T. G., Voors, A. A., Lam, C. S. P., Cowie, M. R., Kjeldsen, K., Jankowska, E. A., Atar, D., Butler, J., et al. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 546

Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management

Cappellini, M. D., Comin‐Colet, J., de Francisco, A., Dignass, A., Doehner, W., Lam, C. S., Macdougall, I. C., Rogler, G., Camaschella, C., Kadir, R., et al. (2017) · American Journal of Hematology

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 502

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 450

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

Heart failure with preserved ejection fraction: from mechanisms to therapies

Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 355

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 352

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Zannad, F., Anker, S. D., Byra, W. M., Cleland, J. G. F., Fu, M., Gheorghiade, M., Lam, C. S. P., Mehra, M. R., Neaton, J. D., Nessel, C. C., et al. (2018) · New England Journal of Medicine

Heart Failure Treatment and ManagementAtrial Fibrillation Management and Outcomes

Cited by 345

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S. P., Rodgers, A., Mahaffey, K. W., Cannon, C. P., Perkovic, V., et al. (2020) · Journal of the American Heart Association

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 247

Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction

Borlaug, B. A., Jaber, W. A., Ommen, S. R., Lam, C. S. P., Redfield, M. M., & Nishimura, R. A. (2011) · Heart

Cardiovascular Function and Risk FactorsCardiovascular and exercise physiology

Cited by 229

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 223

Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease

Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 185

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Influence of sex and hormone status on circulating natriuretic peptides

Lam, C. S. P., Cheng, S., Choong, K., Larson, M. G., Murabito, J. M., Newton-Cheh, C., Bhasin, S., McCabe, E. L., Miller, K. K., Redfield, M. M., et al. (2011) · Journal of the American College of Cardiology

Hormonal and reproductive studiesHeart Failure Treatment and Management

Cited by 181